Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Depression: HELP
Articles from Ohio
Based on 1,497 articles published since 2008

These are the 1497 published articles about Depression that originated from Ohio during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. 2019

Anonymous3491079 / Curry, Susan J / Krist, Alex H / Owens, Douglas K / Barry, Michael J / Caughey, Aaron B / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Grossman, David C / Kemper, Alex R / Kubik, Martha / Landefeld, C Seth / Mangione, Carol M / Silverstein, Michael / Simon, Melissa A / Tseng, Chien-Wen / Wong, John B. ·University of Iowa, Iowa City. · Fairfax Family Practice Residency, Fairfax, Virginia. · Virginia Commonwealth University, Richmond. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California. · Stanford University, Stanford, California. · Harvard Medical School, Boston, Massachusetts. · Oregon Health & Science University, Portland. · Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Kaiser Permanente Washington Health Research Institute, Seattle. · Nationwide Children's Hospital, Columbus, Ohio. · Temple University, Philadelphia, Pennsylvania. · University of Alabama at Birmingham. · University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · University of Hawaii, Honolulu. · Pacific Health Research and Education Institute, Honolulu, Hawaii. · Tufts University, Medford, Massachusetts. ·JAMA · Pubmed #30747971.

ABSTRACT: Importance: Perinatal depression, which is the occurrence of a depressive disorder during pregnancy or following childbirth, affects as many as 1 in 7 women and is one of the most common complications of pregnancy and the postpartum period. It is well established that perinatal depression can result in adverse short- and long-term effects on both the woman and child. Objective: To issue a new US Preventive Services Task Force (USPSTF) recommendation on interventions to prevent perinatal depression. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of preventive interventions for perinatal depression in pregnant or postpartum women or their children. The USPSTF reviewed contextual information on the accuracy of tools used to identify women at increased risk of perinatal depression and the most effective timing for preventive interventions. Interventions reviewed included counseling, health system interventions, physical activity, education, supportive interventions, and other behavioral interventions, such as infant sleep training and expressive writing. Pharmacological approaches included the use of nortriptyline, sertraline, and omega-3 fatty acids. Findings: The USPSTF found convincing evidence that counseling interventions, such as cognitive behavioral therapy and interpersonal therapy, are effective in preventing perinatal depression. Women with a history of depression, current depressive symptoms, or certain socioeconomic risk factors (eg, low income or young or single parenthood) would benefit from counseling interventions and could be considered at increased risk. The USPSTF found adequate evidence to bound the potential harms of counseling interventions as no greater than small, based on the nature of the intervention and the low likelihood of serious harms. The USPSTF found inadequate evidence to assess the benefits and harms of other noncounseling interventions. The USPSTF concludes with moderate certainty that providing or referring pregnant or postpartum women at increased risk to counseling interventions has a moderate net benefit in preventing perinatal depression. Conclusions and Recommendation: The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions. (B recommendation).

2 Guideline Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. 2014

Andersen, Barbara L / DeRubeis, Robert J / Berman, Barry S / Gruman, Jessie / Champion, Victoria L / Massie, Mary Jane / Holland, Jimmie C / Partridge, Ann H / Bak, Kate / Somerfield, Mark R / Rowland, Julia H / Anonymous2830791. ·Barbara L. Andersen, The Ohio State University, Columbus, OH · Robert J. DeRubeis, University of Pennsylvania, Philadelphia, PA · Barry S. Berman, Broward Health Medical Center, Fort Lauderdale, FL · Jessie Gruman, Center for Advancing Health, Washington, DC · Victoria L. Champion, Indiana University, Indianapolis, IN · Mary Jane Massie, Jimmie C. Holland, Memorial Sloan-Kettering Cancer Institute, New York, NY · Ann H. Partridge, Dana Farber Cancer Institute, Boston, MA · Kate Bak and Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA · Julia H. Rowland, National Cancer Institute, Bethesda, MD. ·J Clin Oncol · Pubmed #24733793.

ABSTRACT: PURPOSE: A Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer was identified for adaptation. METHODS: American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The guideline was reviewed for developmental rigor and content applicability. RESULTS: On the basis of content review of the pan-Canadian guideline, the ASCO panel agreed that, in general, the recommendations were clear, thorough, based on the most relevant scientific evidence, and presented options that will be acceptable to patients. However, for some topics addressed in the pan-Canadian guideline, the ASCO panel formulated a set of adapted recommendations based on local context and practice beliefs of the ad hoc panel members. It is recommended that all patients with cancer be evaluated for symptoms of depression and anxiety at periodic times across the trajectory of care. Assessment should be performed using validated, published measures and procedures. Depending on levels of symptoms and supplementary information, differing treatment pathways are recommended. Failure to identify and treat anxiety and depression increases the risk for poor quality of life and potential disease-related morbidity and mortality. This guideline adaptation is part of a larger survivorship guideline series. CONCLUSION: Although clinicians may not be able to prevent some of the chronic or late medical effects of cancer, they have a vital role in mitigating the negative emotional and behavioral sequelae. Recognizing and treating effectively those who manifest symptoms of anxiety or depression will reduce the human cost of cancer.

3 Editorial Foreword: Update on the Treatment of Depression and Pharmacogenomics Testing in Children and Adolescents: Dr. Strawn and Colleagues. 2018

Pascoe, John M. ·Wright State University, Dayton, OH. Electronic address: john.pascoe@wright.edu. ·Curr Probl Pediatr Adolesc Health Care · Pubmed #29477218.

ABSTRACT: -- No abstract --

4 Editorial Deaths of Despair: Why? What to Do? 2017

Scutchfield, F Douglas / Keck, C William. ·F. Douglas Scutchfield is the Bosomworth professor emeritus in the College of Public Health and College of Medicine, University of Kentucky, Lexington. C. William Keck is professor emeritus in the Department of Family and Community Medicine, Northeast Ohio Medical University, Rootstown. ·Am J Public Health · Pubmed #28902554.

ABSTRACT: -- No abstract --

5 Editorial Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris. 2016

Schrom, Kory / Nagy, Terri / Mostow, Eliot. ·Northeast Ohio Medical University, Rootstown, Ohio. Electronic address: kschrom@neomed.edu. · Akron Dermatology, Akron, Ohio. · Northeast Ohio Medical University, Rootstown, Ohio; Akron Dermatology, Akron, Ohio. ·J Am Acad Dermatol · Pubmed #27317530.

ABSTRACT: Isotretinoin is used to treat severe and recalcitrant acne. Possible side effects include depression, suicide, and suicidal ideation; however, other studies suggest isotretinoin may improve mood and quality of life. Although iPLEDGE consenting warns about the risk of depression and suicidal ideation, there is no recommendation for screening tools. The patient health questionnaire-2 and the patient health questionnaire-9 are validated instruments that enable dermatologists to efficiently screen for depression before and after isotretinoin is initiated.

6 Editorial Double TEAM: Enhancing Response and Treating Depression in Patients With Bipolar Disorder During a Mixed or Manic Episode. 2015

Kowatch, Robert. ·Ohio State Wexner Medical Center/Nationwide Children's Hospital, Columbus. Electronic address: robert.kowatch@nationwidechildrens.org. ·J Am Acad Child Adolesc Psychiatry · Pubmed #26598471.

ABSTRACT: -- No abstract --

7 Editorial Beyond Blame: Parents as Partners. 2015

Kelleher, Kelly J / Hoagwood, Kimberly. ·Colleges of Medicine and Public Health, The Ohio State University, Columbus, Ohio. Electronic address: Kelly.Kelleher@nationwidechildrens.org. · Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York. ·J Pediatr · Pubmed #26276224.

ABSTRACT: -- No abstract --

8 Editorial Connecting the dots--establishing causality between chronic stress, depression, and cardiovascular disease. 2014

DiVincenzo, Lola / Reber, Megan / Perera, Vidushani / Chilian, William M. ·Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio. · Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio wchilian@neomed.edu. ·J Appl Physiol (1985) · Pubmed #25257872.

ABSTRACT: -- No abstract --

9 Editorial Loneliness trajectories. 2013

van Dulmen, Manfred H M / Goossens, Luc. ·Kent State University, Department of Psychology, PO Box 5190, Kent, OH 44242, USA. Electronic address: mvandul@kent.edu. ·J Adolesc · Pubmed #23957958.

ABSTRACT: This special section brings together five studies using group-based modeling to capture developmental trajectories of loneliness from age 7 through age 20. Together, the findings from these studies provide further evidence that developmental trajectories of loneliness are likely not best understood at a continuum but reflect distinct subpopulations that differ both where they start out and how they change over time in terms of mean levels of loneliness. Furthermore, adolescents who show chronically high loneliness or increasing loneliness over time exhibit poorer psychological and physical health, including greater incidence of depressive symptoms and more frequent suicide attempts. The findings from these studies also suggest that individuals experiencing increases in loneliness with age fare worse as well in terms of both physical and psychological health.

10 Editorial Heart-brain medicine: update 2009. 2010

Penn, Marc S / Bakken, Earl E. ·Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH 44195, USA. pennm@ccf.org ·Cleve Clin J Med · Pubmed #20622074.

ABSTRACT: -- No abstract --

11 Review Depressive and Anxiety Symptoms in Adult Congenital Heart Disease: Prevalence, Health Impact and Treatment. 2018

Jackson, Jamie L / Leslie, Carine E / Hondorp, Shawn N. ·Center for Biobehavioral Health, Nationwide Children's Hospital, Columbus, OH, United States of America; Department of Pediatrics, The Ohio State University, Columbus, OH, United States of America. Electronic address: jamie.jackson2@nationwidechildrens.org. · Center for Biobehavioral Health, Nationwide Children's Hospital, Columbus, OH, United States of America. · Department of Psychiatry and Behavioral Medicine, Spectrum Health Medical Group, Grand Rapids, MI, United States of America; College of Human Medicine, Michigan State University, Grand Rapids, MI, United States of America. ·Prog Cardiovasc Dis · Pubmed #30012407.

ABSTRACT: Over 1.4 million adults in the United States are living with congenital heart disease (CHD), which can vary widely in disease burden and risk for future cardiovascular complications. As a result, some CHD survivors may experience greater emotional distress, including symptoms of depression and anxiety. This review summarizes the developing research literature on the prevalence, health impact, as well as screening and treatment of depressive and anxiety symptoms among adult CHD survivors. Additionally, the review will highlight findings from the acquired heart disease literature, a well-studied area that can inform research and clinical care practices for CHD survivors with depressive and/or anxiety symptoms. The review concludes with considerations for depression and anxiety screening in medical settings and identifying referral resources for treatment.

12 Review Psychological treatments for adults and children with epilepsy: Evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. 2018

Michaelis, Rosa / Tang, Venus / Goldstein, Laura H / Reuber, Markus / LaFrance, William Curt / Lundgren, Tobias / Modi, Avani C / Wagner, Janelle L. ·Department of Neurology, Herdecke Community Hospital, University of Witten/Herdecke, Herdecke, Germany. · Integrated Curriculum for Anthroposophical Medicine (ICURAM), Witten/Herdecke University, Herdecke, Germany. · Department of Neurology, Center for Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Austria. · Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Shatin, Hong Kong. · Department of Clinical Psychology, Prince of Wales Hospital, Shatin, Hong Kong. · Department of Psychology, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK. · Academic Neurology Unit, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK. · Departments of Psychiatry and Neurology, Rhode Island Hospital, Brown University, Providence, RI, USA. · Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden. · Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. · College of Nursing and Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA. ·Epilepsia · Pubmed #29917225.

ABSTRACT: Given the significant impact that psychosocial factors and epilepsy treatments can have on the health-related quality of life (HRQOL) of individuals with epilepsy and their families, there is great clinical interest in the role of psychological evaluation and treatments to improve HRQOL and comorbidities. Therefore, the International League Against Epilepsy (ILAE) charged the Psychology Task Force with the development of recommendations for clinical care based on evaluation of the evidence from their recent Cochrane review of psychological treatments in individuals with epilepsy. The literature search for a recent Cochrane review of randomized controlled trials investigating psychological treatments for individuals with epilepsy constitutes the key source of evidence for this article. To provide practical guidance to service providers, we provide ratings on study research designs based on (1) the American Academy of Neurology's Level of Evidence system and (2) the Grading of Recommendations, Assessment, Development, and Evaluation system. This paper is the culmination of an international collaboration process involving pediatric and adult psychologists, neurologists, psychiatrists, and neuropsychiatrists. The process and conclusions were reviewed and approved by the ILAE Executive Committee. The strongest evidence for psychological interventions was identified for the most common mental health problems, including depression, neurocognitive disturbances, and medication adherence. Psychological interventions targeting the enhancement of HRQOL and adherence and a decrease in comorbidity symptoms (anxiety, depression) should be incorporated into comprehensive epilepsy care. There is a range of psychological strategies (ie, cognitive behavioral therapy and mindfulness-based therapies) that show promise for improving the lives of persons with epilepsy, and clinical recommendations are provided to assist epilepsy health care providers in treating the comorbidities and challenges associated with epilepsy and its treatments.

13 Review Perinatal SSRI medications and offspring hippocampal plasticity: interaction with maternal stress and sex. 2018

Pawluski, Jodi L / Gemmel, Mary. ·Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR_S 1085, F-35000, Rennes, France. Jodi-lynn.pawluski@univ-rennes1.fr. · Department of Biological Sciences, Ohio University, Athens, OH, USA. ·Hormones (Athens) · Pubmed #29858853.

ABSTRACT: There is growing use of selective serotonin reuptake inhibitor antidepressant (SSRI) medications during the perinatal period to treat maternal affective disorders. Perinatal SSRI exposure can have a long-term impact on offspring neuroplasticity and behavioral development that remains to be fully elucidated. This mini-review will summarize what is known about the effects of perinatal SSRIs on plasticity in the developing hippocampus, taking into account the role that maternal stress and depression may have. Emerging clinical findings and research in animal models will be discussed. In addition, sexually differentiated effects will be highlighted, as recent work shows that male offspring are often more sensitive to the effects of maternal stress, whereas female offspring can be more sensitive to perinatal SSRIs. Potential mechanisms behind these changes and aims for future research will also be discussed. Understanding the impact of perinatal SSRIs on neuroplasticity will provide better insight into the long-term effects of such medications on the health and well-being of both mother and child and may improve therapeutic approaches for maternal mood disorders during the perinatal period.

14 Review Consequences of Antepartum Depression. 2018

Schaffir, Jonathan. ·Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio. ·Clin Obstet Gynecol · Pubmed #29659372.

ABSTRACT: To counsel women about risks and benefits of depression treatment during pregnancy, clinicians must appreciate the potential consequences of untreated depression on the mother and her unborn child. Many studies have demonstrated associations between untreated depression during pregnancy and a range of adverse outcomes, including low birth weight, preterm delivery, preeclampsia, emergent operative delivery, postpartum depression, and both cognitive and behavioral deficits in the child. Although most of these associations are marked by low odds ratios and a host of potential confounding issues, they collectively provide considerable rationale for identifying depression in pregnancy and offering treatment for mothers at risk.

15 Review The Neuropsychological Consequences of Armed Conflicts and Torture. 2018

Weisleder, Pedro / Rublee, Caitlin. ·Division of Neurology, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. weisleder.1@osu.edu. · Department of Emergency Medicine, The Ohio State University, Columbus, OH, USA. ·Curr Neurol Neurosci Rep · Pubmed #29445906.

ABSTRACT: PURPOSE OF REVIEW: At any point in time, there are hundreds of armed conflicts throughout the world. Neuropsychological disorders are a major cause of morbidity during and after armed conflicts. Conditions such as closed and open head injuries, acute stress disorder, post-traumatic stress disorder, depression, anxiety, and psychosis are prevalent among survivors. Herein, we summarize information on the various forms of torture, the resultant neuropsychological pathology, and treatment strategies to help survivors. RECENT FINDINGS: Strategies to address the needs of individuals who experienced neuropsychological trauma due to armed conflicts and torture include pharmacological and psychological interventions. The former includes antidepressant, antianxiety, and antipsychotic medications. The latter includes narrative exposure therapy and trauma-focused cognitive-behavioral therapy. Neuropsychological disorders are major causes of morbidity among survivors of armed conflicts and torture. Treatment strategies must be affordable, applicable across cultures, and deliverable by individuals who understand the victims' psychosocial and ethnic background.

16 Review Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. 2018

Luft, Marissa J / Lamy, Martine / DelBello, Melissa P / McNamara, Robert K / Strawn, Jeffrey R. ·Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH 45267-0559. · Department of Pediatrics, Division of Child & Adolescent Psychaitry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229. · Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH 45267-0559; Department of Pediatrics, Division of Child & Adolescent Psychaitry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229. · Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH 45267-0559; Department of Pediatrics, Division of Child & Adolescent Psychaitry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229. Electronic address: strawnjr@ucmail.uc.edu. ·Curr Probl Pediatr Adolesc Health Care · Pubmed #29358037.

ABSTRACT: The tolerability of antidepressants is poorly characterized in children and adolescents with depressive and anxiety disorders. Among adverse events that affect the tolerability of antidepressants in youth is activation, a cluster of symptoms that represent a hyperarousal event characterized by impulsivity, restlessness, and/or insomnia. This cluster of symptoms was first identified as a side effect of selective serotonin and selective serotonin norepinephrine inhibitors (SSRIs and SSNRIs) in the early 1990s; however, activation remains poorly characterized in terms of prevalence, risk factors, and pathophysiology. This article describes the pathophysiology of antidepressant-related activation, predictors of activation and its clinical management in youth with depressive and anxiety disorders who are treated with antidepressant medications.

17 Review Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. 2018

Wehry, Anna M / Ramsey, Laura / Dulemba, Shane E / Mossman, Sarah A / Strawn, Jeffrey R. ·University of Cincinnati, College of Medicine, Box 0559, Cincinnati, OH 45267-0559. · Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. · Division of Child and Adolescent, Cincinnati Children's Hospital, Cincinnati, OH. · University of Cincinnati, College of Medicine, Box 0559, Cincinnati, OH 45267-0559. Electronic address: strawnjr@ucmail.uc.edu. ·Curr Probl Pediatr Adolesc Health Care · Pubmed #29325731.

ABSTRACT: Significant advances have been made in the application of pharmacogenomic testing for the treatment of patients with psychiatric disorders. Over the past decade, a number of studies have evaluated the utility of pharmacogenomic testing in pediatric patients with psychiatric disorders. The evidence base for pharmacogenomic testing in youth with depressive and anxiety disorders as well as attention/deficit hyperactivity disorder (ADHD) is reviewed in this article. General pharmacogenomic principles are summarized and functional polymorphisms in P450 enzymes (and associated metabolizer phenotypes), the serotonin transporter promoter polymorphisms, serotonin 2A receptor genes (e.g., HT2AR) and catecholamine pathway genes (e.g., COMT) are reviewed. These commonly tested pharmacogenomic markers are discussed with regard to studies of drug levels, efficacy and side effects. The translation of pharmacogenomics to individualized/precision medicine in pediatric patients with ADHD, anxiety and depressive disorders has accelerated; however, its application remains challenging given that there are numerous divergent pathways between medication/medication dose and clinical response and side effects. Nonetheless, by leveraging variations in individual genes that may be relevant to medication metabolism or medication target engagement, pharmacogenomic testing may have a role in predicting treatment response, side effects and medication selection in youth with ADHD, depressive and anxiety disorders.

18 Review Perinatal selective serotonin reuptake inhibitor medication (SSRI) effects on social behaviors, neurodevelopment and the epigenome. 2018

Gemmel, Mary / Bögi, Eszter / Ragan, Christina / Hazlett, Mariah / Dubovicky, Michal / van den Hove, Daniel L / Oberlander, Tim F / Charlier, Thierry D / Pawluski, Jodi L. ·Department of Biological Sciences, Ohio University, Athens, OH, USA. · Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia. · Department of Psychology, Colgate University, Hamilton, NY, USA. · Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; Division of Molecular Psychiatry, Laboratory of Translational Neuroscience, Center of Mental Health, University of Wuerzburg, Wuerzburg, Germany. · Department of Pediatrics, University of British Columbia, B.C. Children's and Women's Hospitals, BC Children's Hospital Research Institute, Vancouver, Canada. · Research Institute in Health, Environment and Occupation, Institut National de la Santé et de la Recherche Médicale U1085, Université de Rennes 1, Rennes, France. · Research Institute in Health, Environment and Occupation, Institut National de la Santé et de la Recherche Médicale U1085, Université de Rennes 1, Rennes, France. Electronic address: j.pawluski@gmail.com. ·Neurosci Biobehav Rev · Pubmed #28472631.

ABSTRACT: Recent research has linked early life exposure to selective serotonin reuptake inhibitor medications (SSRIs) to modifications of social behaviors in children. Serotonin is a key regulator of neurodevelopment, social behaviors and mental health, and with the growing use of SSRIs to treat maternal affective disorders during the perinatal period, questions have been raised about the benefits and risks of perinatal SSRI exposure on the developing child. This review will highlight how perinatal SSRIs affect maternal care and neurodevelopmental outcomes related to social affiliative behaviors in offspring; such as play behaviors, social interactions, reproductive behaviors, and maternal care of the next generation. We will also review how early life exposure to SSRIs can alter related neurobiology, and the epigenome. Both clinical research and findings from animal models will be discussed. Understanding the impact of perinatal SSRIs on neurobehavioral outcomes will improve the health and well-being of subsequent generations.

19 Review Postpartum Depression: What Do Pediatricians Need to Know? 2017

Sriraman, Natasha K / Pham, Do-Quyen / Kumar, Reeti. ·Division of General Academic Pediatrics, The Children's Hospital of the King's Daughters; Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA. · Division of Adolescent Medicine, Seattle Children's Hospital, University of Washington, Seattle, WA. · Division of Nephrology, Nationwide Children's Hospital, Columbus, OH. ·Pediatr Rev · Pubmed #29196509.

ABSTRACT: -- No abstract --

20 Review The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. 2017

Goldstein, Benjamin I / Birmaher, Boris / Carlson, Gabrielle A / DelBello, Melissa P / Findling, Robert L / Fristad, Mary / Kowatch, Robert A / Miklowitz, David J / Nery, Fabiano G / Perez-Algorta, Guillermo / Van Meter, Anna / Zeni, Cristian P / Correll, Christoph U / Kim, Hyo-Won / Wozniak, Janet / Chang, Kiki D / Hillegers, Manon / Youngstrom, Eric A. ·Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Canada. · Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada. · Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. · Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA. · Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA. · Department of Psychiatry & Behavioral Sciences, The Johns Hopkins University, Baltimore, MD, USA. · Ohio State University Wexner Medical Center/Nationwide Children's Hospital, Columbus, OH, USA. · Department of Psychiatry, UCLA, Los Angeles, CA, USA. · Division of Health Research, Lancaster University, Lancaster, UK. · Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA. · Department of Psychiatry, University of Texas, Houston, TX, USA. · The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA. · Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA. · Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. · Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. · Department of Psychiatry, Stanford University, Palo Alto, CA, USA. · Department of Child and Adolescent Psychiatry and Psychology, Erasmus Medical Center-Sophia, Rotterdam, The Netherlands. · Department of Psychology and Neuroscience, University of North Carolina, Chapel Hill, NC, USA. ·Bipolar Disord · Pubmed #28944987.

ABSTRACT: OBJECTIVES: Over the past two decades, there has been tremendous growth in research regarding bipolar disorder (BD) among children and adolescents (ie, pediatric BD [PBD]). The primary purpose of this article is to distill the extant literature, dispel myths or exaggerated assertions in the field, and disseminate clinically relevant findings. METHODS: An international group of experts completed a selective review of the literature, emphasizing areas of consensus, identifying limitations and gaps in the literature, and highlighting future directions to mitigate these gaps. RESULTS: Substantial, and increasingly international, research has accumulated regarding the phenomenology, differential diagnosis, course, treatment, and neurobiology of PBD. Prior division around the role of irritability and of screening tools in diagnosis has largely abated. Gold-standard pharmacologic trials inform treatment of manic/mixed episodes, whereas fewer data address bipolar depression and maintenance/continuation treatment. Adjunctive psychosocial treatment provides a forum for psychoeducation and targets primarily depressive symptoms. Numerous neurocognitive and neuroimaging studies, and increasing peripheral biomarker studies, largely converge with prior findings from adults with BD. CONCLUSIONS: As data have accumulated and controversy has dissipated, the field has moved past existential questions about PBD toward defining and pursuing pressing clinical and scientific priorities that remain. The overall body of evidence supports the position that perceptions about marked international (US vs elsewhere) and developmental (pediatric vs adult) differences have been overstated, although additional research on these topics is warranted. Traction toward improved outcomes will be supported by continued emphasis on pathophysiology and novel therapeutics.

21 Review The psychosocial burden of psoriatic arthritis. 2017

Husni, M Elaine / Merola, Joseph F / Davin, Sara. ·Cleveland Clinic, Main Campus, 9500 Euclid Ave, Cleveland, OH 44195. Electronic address: husnie@ccf.org. · Brigham and Women׳s Hospital and Harvard Medical School, Boston, MA. · Cleveland Clinic, Main Campus, 9500 Euclid Ave, Cleveland, OH 44195. ·Semin Arthritis Rheum · Pubmed #28802776.

ABSTRACT: OBJECTIVE: To assess the psychosocial impact of psoriatic arthritis (PsA), describe how health-related quality of life (QoL) is affected in patients with PsA, discuss measures used to evaluate the psychosocial impact of PsA, and review studies examining the effect of therapy on QoL. METHODS: A targeted review on the impact of PsA on QoL and the role of tailored psychosocial management in reducing the psychosocial burden of the disease was performed. PubMed literature searches were conducted using the terms PsA, psychosocial burden, QoL, and mood/behavioral changes. Articles were deemed relevant if they presented information regarding the psychosocial impact of PsA, methods used to evaluate these impacts, or ways to manage/improve management of PsA and its resulting comorbidities. The findings of this literature search are descriptively reviewed and the authors׳ expert opinion on their interpretation is provided. RESULTS: The psychosocial burden of PsA negatively affects QoL. Patients suffer from sleep disorders, fatigue, low-level stress, depression and mood/behavioral changes, poor body image, and reduced work productivity. Additionally, each patient responds to pain differently, depending on a variety of psychological factors including personality structure, cognition, and attention to pain. Strategies for evaluating the burdens associated with PsA and the results of properly managing patients with PsA are described. CONCLUSIONS: PsA is associated with a considerable psychosocial burden and new assessment tools, specific to PsA, have been developed to help quantify this burden in patients. Future management algorithms of PsA should incorporate appropriate assessment and management of psychological and physical concerns of patients. Furthermore, patients with PsA should be managed by a multidisciplinary team that works in coordination with the patient and their family or caregivers.

22 Review The Lived Experience of Anemia Without a Cause. 2017

O'Malley, Patricia. ·Department of Nursing Research, Premier Health, Center of Nursing Excellence, 1 Wyoming Street, Dayton, OH 45409, USA; School of Nursing, Indiana University East, 2325 Chester Boulevard, Richmond, IN 47374, USA. Electronic address: pomalley@premierhealth.com. ·Crit Care Nurs Clin North Am · Pubmed #28778298.

ABSTRACT: This article explores anemia without an obvious cause from two perspectives: a patient and the evidence. Although evidence is required to drive favorable patient outcomes, the focus on evidence often hides the patient experience during diagnosis and treatment. Knowledge of experience with evidence can provide a deeper perspective for clinical decision making and meet nursing's ethical mandate to relieve suffering. Although one patient experience does not reflect every patient experience, this patient's experience demonstrates how difficult and dark anemia can be.

23 Review The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. 2017

Aftab, Awais / Gao, Keming. ·a Department of Psychiatry, Residency Training Program , University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine , Cleveland , OH , USA. · b Mood and Anxiety Clinic in the Mood Disorders Program, Department of Psychiatry , University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine , Cleveland , OH , USA. ·Expert Opin Drug Discov · Pubmed #28718334.

ABSTRACT: INTRODUCTION: Brexpiprazole is the most recently approved second-generation antipsychotic, which is used as adjunctive therapy to antidepressants for treating major depressive disorder (MDD) with inadequate response. Brexpiprazole shares pharmacological similarities with other second-generation antipsychotics, especially aripiprazole. Area covered: This review provides a detailed overview of the pre-clinical studies of brexpiprazole, followed by a summary of its clinical studies, and a comparison with other antipsychotics in MDD. Brexpiprazole is superior to placebo in reducing depressive symptoms of patients who have had an inadequate response to a standard antidepressant treatment. The efficacy of brexpiprazole is comparable to aripiprazole and quetiapine-XR, but brexpiprazole has demonstrated a lower risk for akathisia than aripiprazole and a lower risk for somnolence than quetiapine-XR. Expert opinion: Given that different studies have used different criteria to define 'treatment-resistance' or 'inadequate-response', an accurate comparison of the efficacy and safety of brexpiprazole with other antipsychotics is difficult. Preclinical data supports the premise that the antidepressant-like effects of antipsychotics are mainly due to their ability to modulate/regulate the monoamine system. Therefore, antipsychotics with similar pharmacodynamic properties like brexpiprazole could also take the 'me too' approach to treating MDD.

24 Review Psychosocial Patient-Reported Outcomes in Pediatric and Adolescent Diabetes: a Review and Case Example. 2017

Corathers, Sarah D / Mara, Constance A / Chundi, Pavan K / Kichler, Jessica C. ·Division of Endocrinology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7012, Cincinnati, OH, 45229, USA. sarah.corathers@cchmc.org. · James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. sarah.corathers@cchmc.org. · Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. · James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. ·Curr Diab Rep · Pubmed #28508255.

ABSTRACT: PURPOSE OF REVIEW: The purpose of this review is to define psychosocial patient-reported outcomes (PROs) relevant to pediatric and adolescent diabetes populations. Potential domains for PROs include a spectrum of emotional, behavioral, social, physical, overall health, and/or care management areas. A literature review of potential PRO measures, selection criteria, and implementation strategies including a case example will be presented. RECENT FINDINGS: Among the pediatric, adolescent, and emerging adult populations, research indicates a relative higher risk for distress, depression, anxiety, and eating disorders as compared to peers without diabetes. Use of PRO measures can expand providers' focus beyond glycemic control, or simply hemoglobin A1c, to better appreciate the impact of diabetes on the whole child/adolescent, and provide services that address patients' individually identified needs, which are most salient to them. Successful selection and implementation of psychosocial PRO measures should be designed to include pathways for real-time provider interaction with the patient and respective PRO data to guide clinical care.

25 Review Occupational Therapy Interventions for Adults With Traumatic Brain Injury. 2017

Wheeler, Steven / Acord-Vira, Amanda / Arbesman, Marian / Lieberman, Deborah. ·Steven Wheeler, PhD, OTR/L, CBIS, is Professor, Rehabilitation Sciences, and Program Director, Occupational Therapy, University of Cincinnati, OH; steven.wheeler@uc.edu. · Amanda Acord-Vira, MOT, OTR/L, CBIS, is Assistant Professor, Division of Occupational Therapy, West Virginia University, Morgantown. · Marian Arbesman, PhD, OTR/L, is Methodology Consultant, Evidence-Based Practice Project, American Occupational Therapy Association, Bethesda, MD; President, ArbesIdeas, Inc., Williamsville, NY; and Adjunct Assistant Professor, Department of Rehabilitation Science, University at Buffalo, NY. · Deborah Lieberman, MSHA, OTR/L, FAOTA, is Director, Evidence-Based Practice Project, and Staff Liaison to the Commission on Practice, American Occupational Therapy Association, Bethesda, MD. ·Am J Occup Ther · Pubmed #28422643.

ABSTRACT: This Evidence Connection describes a case report of an adult with traumatic brain injury (TBI), applying the evidence for intervention from the systematic reviews on TBI that were conducted in conjunction with the American Occupational Therapy Association's (AOTA's) Evidence-Based Practice Project. The occupational therapy assessment and treatment processes for hospital, home, and community settings are described. Evidence Connection articles provide a clinical application of systematic reviews developed in conjunction with AOTA's Evidence-Based Practice Project.